Genetic Signatures Obtains FDA Clearance for Gastrointestinal Parasite Detection Kit

MT Newswires Live06-04

Diagnostics company Genetic Signatures’ (ASX:GSS) EasyScreen Gastrointestinal Parasite Detection Kit and GS1 automated workflow secured Food & Drug Administration clearance for marketing and sale in the US, according to a Tuesday filing with the Australian Securities Exchange.

The company has installed instruments and completed training at nine sites, including hospitals, health departments and corporate pathology providers, under a customer experience program in preparation for the kit’s commercial launch, the filing said.

Once a properly packed and labeled product is available and the company's pathology provider customers have finished their internal technological evaluation and approval procedure, the first commercial sale is expected to occur within 60 to 90 days of clearance, according to the filing.

Price (AUD): $0.73, Change: $, Percent Change: %

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment